ReShape Lifesciences shareholders authorize reverse stock split up to 1:60 and elect directors

Proposal 5 : The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, as set forth below. Votes For Votes Against Abstentions 6,988,147 ​ 1,127,305 ​ 236,602

Proposal 2 : The Company’s stockholders authorized the Company’s Board of Directors (the “Board”), in its discretion but in no event later than February 23, 2025, which is one year after the date of the Annual Meeting, to amend the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-10 to 1-for-60, such ratio to be determined by the Board and included in a public announcement, as set forth below. Votes For Votes Against Abstentions 5,751,242 ​ 2,584,917 ​ 15,895

Proposal 3 : The Company’s stockholders approved the issuance of shares of the Company’s common stock underlying warrants issued to an investor pursuant to that certain Inducement Offer to Exercise Common Stock Purchase Warrants, dated as of November 21, 2023, in an amount equal to 20% or more of the Company’s common stock outstanding before the issuance of such warrants upon the operation of anti-dilution provisions contained in such warrants, as required by and in accordance with Nasdaq Listing Rule 5635(d), as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 1,158,808 ​ 801,271 ​ 59,092 ​ 6,332,883

Proposal 1 : The Company’s stockholders elected Dan W. Gladney and Lori McDougal as Class I directors to hold office until the 2026 annual meeting of stockholders or until his or her successor is elected and qualified, or, if sooner, until his or her death, resignation or removal, as set forth below. ​ ​ ​ Votes For Votes Withheld Broker Non-Votes ​ Dan W. Gladney ​ 1,387,535 ​ 631,636 ​ 6,332,883 ​ Lori McDougal ​ 1,511,604 ​ 507,567 ​ 6,332,883

Proposal 4 : The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 1,144,098 ​ 847,403 ​ 27,670 ​ 6,332,883